JPX · 4588.T
Oncolys BioPharma Inc.
¥7,560+¥160 (+2.16%)
Oncolys BioPharma Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.5% below the high.
Loading market information…
JPX · 7774.T · JPY
Stock price, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
Japan Tissue Engineering Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 32.15% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Japan Tissue Engineering Co., Ltd.’s next earnings report is currently expected on Jan 29, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Japan Tissue Engineering Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Japan Tissue Engineering Co., Ltd. operates within the regenerative medicine sector in Japan. The company's activities are organized into three core divisions: Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Development Support. It manufactures and delivers autologous cultured tissues, such as epidermis, cartilage, corneal epithelium, and oral mucosal epithelium, to medical institutions for therapeutic applications. The firm also produces other advanced tissue-engineered medical products. Furthermore, Japan Tissue Engineering is involved in the research and development of three-dimensional human cultured tissue models, which are utilized in the development of external-use cosmetics and drugs, as well as for scientific investigations concerning skin and corneal tissues. Additionally, the company provides comprehensive contract development and manufacturing services for regenerative medicine. Established in 1999, Japan Tissue Engineering Co., Ltd. is based in Gamagori, Japan, and functions as a subsidiary of Teijin Limited.
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:20 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
¥7,560+¥160 (+2.16%)
Oncolys BioPharma Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.5% below the high.
¥559+¥7 (+1.27%)
Astena Holdings Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 0.53% below the high.
¥2,107-¥3 (-0.14%)
Fuso Pharmaceutical Industries,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 16.72% below the high.
¥638-¥9 (-1.39%)
RaQualia Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.45% below the high.
¥411-¥11 (-2.61%)
Stella Pharma Corporation’s quoted price sits in the lower half of its reported 52-week range, 58.69% below the high.
¥749-¥17 (-2.22%)
CanBas Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 24.42% below the high.
¥972-¥3 (-0.31%)
Ohki Healthcare Holdings Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 33.97% below the high.
¥122-¥4 (-3.17%)
ReproCELL Incorporated’s quoted price sits in the lower half of its reported 52-week range, 40.2% below the high.
